Business ❯ Pharmaceuticals ❯ Acquisitions

Biopharmaceuticals

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

The $14-per-share agreement brings Lilly a clinical portfolio targeting chronic inflammation, with closing targeted in the first half of 2026.

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline